Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

pharmiweb.com today archive

2615 PWToday Stories

Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

30 Oct 17

Tokyo, Japan, Basking Ridge, NJ, and Berlin, Germany – (October 30, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody PankoMab-GEX®.

 

Under the terms of the agreement, once a feasibility study has been successfully completed, Daiichi Sankyo has the right to exercise its option for worldwide exclusive rights to develop and commercialize PankoMab-GEX ADC. If Daiichi Sankyo exercises these rights, Glycotope will receive an upfront payment as well as development and sales milestone payments plus royalties. Specific financial terms have not been disclosed.

 

“This strategic partnership is part of our overall strategy to maximize the potential of our ADC technology by seeking partnerships where our proprietary linker and payload as well as our unique protein engineering capabilities can be applied to new antibodies and targets,” said Tom Held, Vice President, Global Head, Antibody Drug Conjugate Task Force, Daiichi Sankyo. “We look forward to working with Glycotope to combine our scientific expertise to develop a new ADC that can deliver smart chemotherapy to cancer cells.”

 

“Entering into this agreement with such a renowned partner as Daiichi Sankyo is an important achievement for Glycotope’s core expertise of tumor-targeted monoclonal antibodies,” said Roland Sand, Chairman of the Board, Glycotope.

 

“We are excited about the opportunity to enter into this collaboration with Daiichi Sankyo, which without doubt adds great value to our glycoepitope-targeting program as well as the oncological pipeline,” added Henner Kollenberg, Managing Director, Glycotope. 

 

ADCs are a type of targeted cancer medicine that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Daiichi Sankyo’s proprietary ADC technology is designed to deliver enhanced cancer cell destruction upon release inside the cell and reduce systemic exposure to the chemotherapy payload compared to the way chemotherapy is commonly delivered. PankoMab-GEX® is an investigational monoclonal antibody that enables tumor-specific binding to a novel carbohydrate-induced conformational epitope, the TA-MUC1, which is extensively expressed in many tumor types including ovarian, lung and breast.1

 

About Glycotope

Glycotope, founded in 2000 in Berlin, focuses on the development of innovative immune-oncological products for the treatment of various can

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.